Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

Gérard Socié , Noel Milpied , Ibrahim Yakoub-Agha (1) , Jacques-Olivier Bay (2) , Sabine Furst , Karin Bilger , Felipe Suarez , Mauricette Michallet , Philippe Lewalle , David Liens , Catherine Mathis , Eric Guemas , Jean-Paul Vernant

1 LIRIC - Lille Inflammation Research International Center - U 995
2 CHELTER - Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias

Domaines: Hématologie

Gérard Socié, Noel Milpied, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Sabine Furst, et al.. Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD. Blood Advances, 2019, 3 (2), pp.184-186. ⟨10.1182/bloodadvances.2018028282⟩. ⟨hal-02002136⟩